TRANSGENE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.262 EUR | -3.07% |
|
-3.37% | -7.88% |
| Jun. 03 | Transgene: first patient in phase II study | CF |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Sales 2024 * | 39.2M 42.13M | Sales 2025 * | 49.2M 52.88M | Capitalization | 132M 141M |
|---|---|---|---|---|---|
| Net income 2024 * | -14M -15.05M | Net income 2025 * | -21M -22.57M | EV / Sales 2024 * | 3.87 x |
| Net Debt 2024 * | 20.2M 21.71M | Net Debt 2025 * | 42.1M 45.25M | EV / Sales 2025 * | 3.53 x |
| P/E ratio 2024 * |
-8.68
x | P/E ratio 2025 * |
-5.92
x | Employees | 141 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Transgene
More press releases
| 1 day | -3.23% | ||
| 1 week | -3.52% | ||
| Current month | +1.61% | ||
| 1 month | -6.53% | ||
| 3 months | +7.51% | ||
| 6 months | -11.27% | ||
| Current year | -8.03% |
1 week
1.25
1.32
1 month
1.241.35
Current year
1.031.52
1 year
1.032.03
3 years
1.032.99
5 years
0.813.15
10 years
0.8110.73
| Managers | Title | Age | Since |
|---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 16-03-31 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16-03-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 13-06-18 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 90-12-31 |
| Director/Board Member | 63 | 04-12-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 1.262 | -3.07% | 29 797 |
| 24-06-07 | 1.302 | 0.00% | 10,617 |
| 24-06-06 | 1.302 | +0.15% | 10,244 |
| 24-06-05 | 1.3 | 0.00% | 29,887 |
| 24-06-04 | 1.3 | -0.46% | 36,710 |
Real-time Euronext Paris, June 10, 2024 at 09:17 am EDT
More quotes
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
Calendar
2024-09-24
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.302
EUR
Average target price
3.5
EUR
Spread / Average Target
+168.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.03% | 142M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +0.93% | 22.78B | |
| -10.67% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- TNG Stock
